Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ac-225-HER3-ARC
- Development stage
- Preclinical
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ac-225-HER3-ARC is a first-in-class antibody radio-conjugate (ARC) being developed through a research collaboration between Actinium Pharmaceuticals and AVEO Oncology. The drug consists of AVEO's anti-HER3 (ErbB3) targeting monoclonal antibody conjugated with Actinium-225, a potent alpha-emitting radioisotope, using Actinium's proprietary Antibody Warhead Enabling (AWE) technology platform. HER3 is a receptor overexpressed in various solid tumors, including colorectal, gastric, breast, and non-small cell lung cancers (NSCLC). The mechanism of action involves the targeted delivery of alpha radiation to HER3-expressing cancer cells, which induces lethal double-strand DNA breaks. Preclinical studies have demonstrated potent, dose-dependent anti-tumor activity across multiple HER3-positive tumor models.
- Other names
- Ac-225-HER3 antibody radio-conjugateAc225-HER3 antibody radio-conjugateAc 225-HER3 antibody radio-conjugateActinium-225 HER3 ARCActinium225 HER3 ARCActinium 225 HER3 ARC
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on Ac-225-HER3-ARC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ac-225-HER3-ARC.